PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27025703-6	2016	Dabrafenib enhanced activity of light-stimulated CRAF at low dose and inhibited CRAF signaling at high dose.	dabrafenib	0-10	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	49-53	
29662630-3	2018	Singly, Dabrafenib only weakly suppresses mutant BRAF-induced ERK signaling and can induce ERK paradoxical activation in CRAF-overexpressing cells.	dabrafenib	8-18	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	121-125	
27196768-4	2016	Treatment of GSR cells with GSK2118436 enhanced EGFR-mediated RAS activity, leading to the formation of BRAF-CRAF dimers and transactivation of CRAF.	dabrafenib	28-38	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	109-113	
27196768-4	2016	Treatment of GSR cells with GSK2118436 enhanced EGFR-mediated RAS activity, leading to the formation of BRAF-CRAF dimers and transactivation of CRAF.	dabrafenib	28-38	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	144-148	
27025703-6	2016	Dabrafenib enhanced activity of light-stimulated CRAF at low dose and inhibited CRAF signaling at high dose.	dabrafenib	0-10	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	80-84	
27025703-7	2016	Moreover, dabrafenib increased the protein level of CRAF proteins but not of BRAF proteins.	dabrafenib	10-20	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	52-56	
27025703-8	2016	Increased CRAF levels correlate with elevated RAF signaling in a dabrafenib-dependent manner, independent of light activation.	dabrafenib	65-75	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	10-14	
23844038-6	2013	However, as reported for other BRAF inhibitors, dabrafenib also induced MAPK pathway activation in wild-type BRAF cells through CRAF (RAF1) signalling, potentially explaining the squamous cell carcinomas and keratoacanthomas arising in patients treated with BRAF inhibitors.	dabrafenib	48-58	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	128-132	
23844038-6	2013	However, as reported for other BRAF inhibitors, dabrafenib also induced MAPK pathway activation in wild-type BRAF cells through CRAF (RAF1) signalling, potentially explaining the squamous cell carcinomas and keratoacanthomas arising in patients treated with BRAF inhibitors.	dabrafenib	48-58	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	134-138